[CLSTR]
< Back to situation

[REVISION HISTORY]

Antibody-drug conjugate market development

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-09-30 02:32 UTC → 2026-10-03 09:38 UTC · added removed

The antibody-drug conjugate (ADC) sector is experiencing significant investment and technological evolution. Individual companies are expanding their capabilities through strategic funding and rights acquisitions. For example, acquisitions, such as Cohance Lifesciences is investing Lifesciences’ $18 million to bolster its ADC portfolio via investment in NJ Bio and Aruka Bio, while and Medicus Pharma Ltd. has reached a Ltd.’s $27 million agreement with Pfizer Inc. to acquire worldwide rights to for the early-stage compound CD228V. Broadly, the ADC The market is projected to grow from $14.23 billion in 2025 to $453.9 billion by 2035, maintaining a compound annual growth rate of 12.30%. The industry is transitioning toward Recent developments include the 2025 US FDA approvals of Daiichi Sankyo’s DATROWAY for breast cancer and non-small cell lung cancer treatments. Technological shifts focus on next-generation platforms that prioritize prioritizing improved drug delivery, linker stability, and higher drug-to-antibody ratios. This includes advancements in antibody discovery, where platforms like Converge Bio utilize target-aware design and multiparameter optimization to balance binding affinity with developability. Emerging trends include the development of bispecific ADCs, such as ADCs. For example, NEOK Bio is developing dual-target therapies currently in for ROR1/B7-H3 and EGFR/MUC1, with Phase 1 clinical trial preparation. trials expected to begin in mid-2026. Successful development continues to rely on specialized bioconjugation expertise to manage the interdependence of the antibody, the linker, and the cytotoxic payload.

Versions

  1. 2026-10-03 09:38 UTC Antibody-drug conjugate market development
  2. 2026-09-30 02:32 UTC Antibody-drug conjugate market development

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.